Eli Lilly Acquires Protomer Technologies

Eli Lilly Acquires Sigilon Therapeutics

June 29, 2023

Biotechnology

Eli Lilly agreed to acquire Sigilon Therapeutics in a cash tender offer valuing the biotech at roughly $34.6 million up front plus contingent value rights that could increase total consideration to about $309.6 million. The acquisition brings Sigilon's encapsulated cell therapy platform (including SIG-002 for type 1 diabetes) into Lilly's diabetes and cell-therapy R&D efforts to accelerate development and potential commercialization.

Johnson & Johnson Acquires Proteologix Inc.

May 16, 2024

Biotechnology

Johnson & Johnson has entered into a definitive agreement to acquire privately-held Proteologix, Inc. for $850 million in cash plus potential milestone payments. Proteologix is a San Carlos, California–based biotechnology company developing bispecific antibodies (including PX128 and PX130) for atopic dermatitis and asthma; the deal is expected to close mid-2024 subject to customary conditions.

Merck Acquires Prometheus Biosciences for $10.8 Billion

June 16, 2023

Biotechnology

Merck has agreed to acquire clinical-stage biotechnology company Prometheus Biosciences for $200.00 per share in cash, representing an approximate total equity value of $10.8 billion. The acquisition strengthens Merck's immunology pipeline by adding Prometheus' precision-medicine platform and lead candidate PRA023 (MK-7240) for inflammatory bowel disease and other immune-mediated conditions.

Eli Lilly Acquires Morphic

July 8, 2024

Biotechnology

Eli Lilly agreed to acquire Morphic Holding, Inc. for $57 per share (approximately $3.2 billion) to expand its immunology and gastroenterology pipeline with Morphic's oral integrin therapies, including MORF-057. Lilly commenced a tender offer that was completed (with subsequent second-step merger) and the transaction closed in August 2024.

Astellas Pharma Acquires Propella Therapeutics

November 15, 2023

Biotechnology

Astellas Pharma, through its U.S. subsidiary Astellas US Holding, agreed to acquire privately held biopharmaceutical company Propella Therapeutics for approximately US$175 million. The acquisition gives Astellas ownership of PRL-02, a next-generation long-acting abiraterone prodrug for prostate cancer currently in Phase 1, and is expected to close within Astellas' fiscal year 2023 (ending March 31, 2024).

Syros Pharmaceuticals Merges with TYME Technologies

September 16, 2022

Biotechnology

Syros Pharmaceuticals completed a merger with TYME Technologies, acquiring TYME's pipeline assets and approximately $60 million of net cash at closing. The transaction was accompanied by an oversubscribed $130 million PIPE financing to provide capital for Syros' late-stage hematology programs and early commercialization activities.